Related Experiment Video
Updated: Jun 13, 2026

Determination of Continuity Index Values in Atrial Fibrillation Ablation with Proactive Esophageal Cooling
Published on: April 19, 2024
Recent achievements in the management of Raynaud's phenomenon
Magnus Baumhäkel1, Michael Böhm
1Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. magnus@baumhaekel.de
Abstract:
Raynaud's phenomenon is a clinical disorder with episodic digital ischemic vasospasm triggered by cold- or emotional-stress. It was first mentioned by Maurice Raynaud in 1862 describing "a local asphyxia of the extremities" and was further divided into primary Raynaud's disease and secondary Raynaud's phenomenon, which is often related to connective tissue diseases, but also physical or chemical strain. Though pathophysiology of Raynaud's phenomenon is still poorly understood, systemic and local vascular effects are most likely to be involved in primary Raynaud's disease. In secondary Raynaud's phenomenon additional abnormalities in vascular structure and function may play the major role. Thus, medical treatment of Raynaud's phenomenon remains unsatisfactory, due to limited understanding of pathophysiological mechanisms. This review addresses current evidence for medical treatment of primary and secondary Raynaud's phenomenon with regard to pathophysiological mechanisms as well as future perspectives.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Angina IV: Management
Atherosclerosis III: Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
